This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and the Sentinel Node Oncology Foundation. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this live activity for a maximum of 16.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
USF Health is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 16.30 contact hours may be earned by learners who successfully complete this continuing nursing education activity.
This activity is intended for physicians, residents, fellows, pharmacists, physician assistants, nurses, physical therapists, occupational therapists in the specialties of Plastic & Reconstructive Surgery, General Surgery, Breast Surgery, Medical Oncology, Radiation Oncology, and Lymphedema who treat or are involved in the treatment of patients with cancer.
- Identify cancer initiation and progression in the tumor microenvironment.
- Distinguish the pathways of metastasis by virtue of the lymphatic versus vascular systems.
- Recognize the utility of SLN biopsy in multiple cancers and that SLN may be the primary gateway to cancer metastasis.
- Describe the application of immune check point inhibition to treat cancer.
- Integrate new genetic and mutational analysis information as biomarkers for diagnoses, staging and treatment selection for patients with metastatic cancers.
- Evaluate the potential application of molecular imaging for pinpoint stereotactic radiotherapy.
- Identify secondary lymphedema resulting from cancer treatment and methods to overcome lymphedema.
USF Health adheres to ACCME Standards regarding commercial support of continuing medical education. It is the policy of USF Health that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation. Detailed disclosure will be made in the course syllabus.
The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
Commercial Support Acknowledgment
This CME/CE activity is supported by an unrestricted education grant from Pfizer.
This activity is jointly provided by: